3-N-(tert-butyloxycarbonyl)aminobiphenyl | 141807-33-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-N-(tert-butyloxycarbonyl)aminobiphenyl
• 英文别名: tert-butyl [1,1′-biphenyl]-3-ylcarbamate；tert-butyl N-(3-phenylphenyl)carbamate
• CAS: 141807-33-2
• 化学式: C₁₇H₁₉NO₂
• 分子量: 269.343
• InChiKey: ZNJOMWOSWXEOID-UHFFFAOYSA-N

物化性质

• 沸点：
  364.0±21.0 °C(Predicted)
• 密度：
  1.105±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-N-(tert-butyloxycarbonyl)aminobiphenyl 在 叔丁基锂 、 L-Selectride 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 5.25h， 生成 1-[3'-N-(tert-butyloxycarbonyl)aminobiphenyl-4'-yl]-3,5-O-tetraisopropyl-oxydisilyl-1,4-dihydroxypentane
  参考文献：
  名称：

  A fluorescence-quencher pair for DNA hybridization studies based on hydrophobic base surrogates

  摘要：

  The synthesis of the novel, fluorescent 3-aminobiphenyl-C-nucleoside M as well as the corresponding building block for oligodeoxynucleotide synthesis is described. M was incorporated into oligodeoxynucleotides via standard phosphoramidite chemistry and the thermal stabilities of duplexes with one and three consecutive M-M, M-P, and M-O pairs, where P denotes an unmodified biphenyl C-nucleoside and O a 3,5-dinitrobiphenyl-C-nucleoside, were determined. It was found that duplexes containing three consecutive M-O pairs were the most stable in the series, notably more stable than a duplex with one additional natural G-C pair instead of the modified residues. Furthermore it was found that the fluorescence of M is efficiently quenched in a duplex when placed opposite to the dinitrophenyl unit O. Thus M and O constitute a novel fluorophore/quencher pair that is orthogonal to natural base pairs in its recognition properties enabling its use as highly specific tags with reporting properties. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2006.12.095
• 作为产物：
  描述：

  氨基甲酸叔丁酯 、 3-溴联苯 在 氯化镍二甲氧基乙烷 、 (4,4'-二叔丁基-2,2'-联吡啶)双[(2-吡啶基)苯基]铱(III)六氟磷酸盐 、 4,4'-二叔丁基-2,2'-二吡啶 、 四甲基胍 作用下， 以 乙腈 为溶剂， 反应 48.0h， 以81%的产率得到3-N-(tert-butyloxycarbonyl)aminobiphenyl
  参考文献：
  名称：

  通过光敏镍催化的氨基甲酸酯的N-酰化反应

  摘要：

  报道了在室温下可见光介导的Cbz-胺/ Boc-胺与芳基亲电试剂介导的Ni（II）催化的光氧化还原N-芳基化的高效方法。该方法提供了广泛使用的N-芳族和N-杂芳族氨基甲酸酯产品的通用途径，这些产品可用于合成几种生物活性分子，并且相对于传统的钯催化的布赫瓦尔德反应具有明显的优势。

  DOI：

  10.1021/acs.joc.8b02182

文献信息

• Ligand-Promoted <i>meta</i>-C–H Amination and Alkynylation
  作者：Peng Wang、Gen-Cheng Li、Pankaj Jain、Marcus E. Farmer、Jian He、Peng-Xiang Shen、Jin-Quan Yu

  DOI：10.1021/jacs.6b08942

  日期：2016.10.26

  Using a modified norbornene (methyl bicyclo[2.2.1]hept-2-ene-2-carboxylate) as a transient mediator, meta-C-H amination and meta-C-H alkynylation of aniline and phenol substrates have been developed for the first time. Both the identification of a monoprotected 3-amino-2-hydroxypyridine/pyridone-type ligand and the use of a modified norbornene as a mediator are crucial for the realization of these

  使用改性降冰片烯（甲基双环[2.2.1]庚-2-烯-2-羧酸酯）作为瞬态介质，首次开发了苯胺和苯酚底物的间位CH胺化和间位CH炔基化。单保护的 3-氨基-2-羟基吡啶/吡啶酮型配体的鉴定和使用修饰的降冰片烯作为介体对于实现这两个前所未有的间 CH 转化至关重要。多种底物与间位 CH 胺化和间位 CH 炔化均兼容。包括吲哚、二氢吲哚和吲唑在内的杂环底物的胺化和炔基化以中等至高产率提供所需的产物。
• Vinyl Thianthrenium Tetrafluoroborate: A Practical and Versatile Vinylating Reagent Made from Ethylene
  作者：Fabio Juliá、Jiyao Yan、Fritz Paulus、Tobias Ritter

  DOI：10.1021/jacs.1c06632

  日期：2021.8.25

  The use of vinyl electrophiles in synthesis has been hampered by the lack of access to a suitable reagent that is practical and of appropriate reactivity. In this work we introduce a vinyl thianthrenium salt as an effective vinylating reagent. The bench-stable, crystalline reagent can be readily prepared from ethylene gas at atmospheric pressure in one step and is broadly useful in the annulation chemistry

  乙烯基亲电子试剂在合成中的使用受到了阻碍，因为无法获得实用且具有适当反应性的合适试剂。在这项工作中，我们引入了乙烯基铪盐作为有效的乙烯基化试剂。这种实验室稳定的结晶试剂可以很容易地在大气压下一步由乙烯气体制备，并且广泛用于（杂）环的环化化学、杂环化合物的 N-乙烯基化和钯催化的交叉偶联反应。噻蒽核心的结构特征实现了独特的合成和反应特性，这是其他乙烯基锍衍生物前所未有的。
• Substituted Triazoles as Sodium Channel Blockers
  申请人：Park Min K.

  公开号：US20090074890A1

  公开（公告）日：2009-03-19

  Substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, migraine, headache pain, migraine headache, epilepsy, irritable bowel syndrome, diabetic neuropathy, multiple sclerosis, manic depression and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier (I), (II), (III).

  公式I、II或III所代表的取代三唑化合物，或其药学上可接受的盐。药物组合物包括有效量的本化合物，单独使用或与一个或多个其他治疗活性化合物联合使用，并加入药学上可接受的载体。治疗与钠通道活性相关或由其引起的疾病的方法，包括急性疼痛、慢性疼痛、内脏疼痛、炎性疼痛、神经痛、偏头痛、头痛、偏头痛头痛、癫痫、肠易激综合征、糖尿病性神经病、多发性硬化症、躁郁症等，包括单独使用或与一个或多个其他治疗活性化合物联合使用的有效量的本化合物的给药。一种局部麻醉的给药方法包括给予本发明化合物的有效量，单独使用或与一个或多个其他治疗活性化合物联合使用，并加入药学上可接受的载体(I)、(II)、(III)。
• Biaryl substituted triazoles as sodium channel blockers
  申请人：Chakravarty Prasun K.

  公开号：US20080171777A1

  公开（公告）日：2008-07-17

  Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier.

  公式I，II或III所代表的取代联苯基三唑化合物，或其药学上可接受的盐，以及制造这些化合物和盐的方法。制药组合物包括有效量的本化合物，单独使用或与一个或多个其他治疗活性化合物结合，并带有药学上可接受的载体。治疗与钠通道活性相关或由其引起的疾病的方法，包括例如急性疼痛、慢性疼痛、内脏疼痛、炎性疼痛、神经病性疼痛、癫痫、肠易激综合征、抑郁症、焦虑症、多发性硬化症和躁郁症，包括单独使用或与一个或多个其他治疗活性化合物结合的本化合物的有效量的给药。给予局部麻醉的方法包括给予本发明化合物的有效量，单独使用或与一个或多个其他治疗活性化合物结合，并带有药学上可接受的载体。
• Nickel(0)-catalyzed cross coupling of aryl O-carbamates and aryl triflates with Grignard reagents. Directed ortho metalation-aligned synthetic methods for polysubstituted aromatics via a 1,2-dipole equivalent
  作者：Saumitra Sengupta、Magda Leite、Delio Soares Raslan、Claude Quesnelle、Victor Snieckus

  DOI：10.1021/jo00041a004

  日期：1992.7

  The first Ni(0)-catalyzed cross-coupling reactions of aryl O-carbamates and aryl triflates with Grignard reagents (Scheme I) to give diversely polysubstituted aromatics 2d and 2e (Table I) which feature regiospecificity based on directed ortho metalation (carbamate), minimal beta-hydride elimination (triflate), and dependence on steric and electronic effects are described.